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ABSTRACT

Disclosed herein are methods and materials for producing a
more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods
that comprise introducing an expressible dedifferentiating
polynucleotide sequence into a less developmentally potent
cell, wherein the transfected less developmentally potent cell
becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage
of origin or a different lineage.
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FIG. 9: NanogP8 Sequence

tB~1ID:liID:m:m:m.:*@~:;:~Kt:m:rnwm:~~m:IDt act a a c
atgagtgtggatccagcttgtccccaaagcttgccctgctttgaagaatccgactgtaaa
M S V D P A C P Q 8 L P C F E E 8 D C K
gaatcttcacctatgcctgtgatttgtgggcctgaagaaaactatccatccttgcaaatg
E S S P M P V I C G P E E N Y P S L Q M
tcttctgctgagatgcctcacacagagactgtctctcctcttccttcctccatggatctg
QL. ___ jf ....b. .....E. .....M. .....f'...... H..... Jt ..... E..... Ifl. .... Y. .....$. .... J? ......L .... J? ......9...... Q. __ , __l:'J ..... P.......L

acctITTllttccallaaccafafilaat1aaatctaaIBaflltJIBcaga~aa~ca~ct~gc~ga~g
aatagcaatggtgtga~gcagaaggcctcagcaccca~ctaccccagcctctactctt~c

N S N G V T Q K A S A P T Y P S L Y S S
taccaccagggatgcctggtgaacccgac. . . . tgggaaccttccaatgt£,gag···. ·.caaccaga·c···.·•. c
Y H Q G C L V N P T G N L P M I
S N Q T
tiga~ca:ttiaa~ctiga~ca:cc~ga~cc~ga:ca~cc~gt~ctigaica~cc:ctic
tiga~cattc~gafctigt0catcc~at§ctiga:ca~tc~gg~ctiga~cagtc~ct;c

tataactgtggagaggaatctctgcagtcctgcatgcacttccagccaaattctcctgcc
Y N C G E E S L Q S C M H F Q P N S P A
agtgacttggaggctgccttggaagctgctggggaaggccttaatgtaatacagcagacc
S D L E A A L E A A G E G L N V I Q Q T
actaggtattttagtactccacaaaccatggatttattcctaaactact~catgaacatg

T R Y F S T P Q T M D L F L N Y S M N M
caacctgaagacgtgtga
Q P E D V
agatgagtgaaactgatattactcaatttcagtctggacactggctgaatccttcctctc
ccctcctcccatccctcataggatttttcttgtttggaaaccacgtgttctggtttccat
gatgcctatccagtcaatctcatggagggtggagtatggttggagcctaatcagcgaggt

ccttggctgctaaggacaacattgatagaagccgtctctggctatagataagtagatcta
atactagtttggatatctttaqgatttaqaatctaacctcaaqaataagaaatacaagta
.
.
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Key:
Key:
Lane 3: lOObp ladder
Lane 4: lOµM 5--aza--C
Lane 5: 3µM 5-aza-C
Lane 6: lµM 5-aza-C
Electrophoresis 050101

Lane 7: Negative control
Lane 8: Positive control lx
Lane 9: Positive control 2x
Lane 10: lOObp ladder
Treatment with 10, 3 or 1uM of 5azaC for
21 days, 5 days coculture.
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Electrophoresis 050115
Troponin I and hANP

FIG. 11
GATA-4 and MLC-2v

3 weeks of treatment (3uM BrdU or 5-azaC) and coculture for 7 days
Lane 2: ladder
Lane 3: Troponin I or GATA-4 low RNA of BrdU treatment
Lane 4: Troponin I or GATA-4 high RNA of BrdU treatment
Lane 5: Troponin I or GATA-4 low RNA of 5azaC treatment
Lane 6: Troponin I or GATA-4 high RNA of 5azaC treatment
Lane 7: ladder
Lane 8: hANP or MLC-2v low RNA of BrdU treatment
Lane 9: hANP or MLC-2v high RNA of BrdU treatment

Lane 10: hANP or MLC-2v low RNA of 5azaC treatment
Lane 11: hANP or MLC-2v high RNA of 5azaC treatment

U.S. Patent

Dec. 9, 2014

Sheet 12 of 17

US 8,906,683 B2

FIG. 12
GATA-4 and MLC-2v

Lane 1: lOObp ladder
Lane 2: 3uM combined treatment 3 weeks
Lane 3: 1uM combined treatment 3 weeks
Lane 4: 3uM 5azaC 3 weeks
Lane 5: 3uM BrdU 3 weeks
Lane 6: 3uM Control (nt 12/27)
Lane 7: 3uM combined treatment 3 weeks
Lane 8: luM combined treatment 3 weeks
Lane 9: 3uM 5azaC 3 weeks
Lane 10: 3uM BrdU 3 weeks
Lane 11: 3uM Control (nt 12/27)
Lane 12: lOObp ladder
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GATA-4 and MLC-2v

FIG. 13

Lane 1: DNA ladder
Lane 2: lOuM 5azaC treatment
Lane 3: 3uM 5azaC treatment
Lane 4: luM 5azaC treatment
Lane 5: 3uM 5azaC treatment
Lane 6: 3uM BrdU treatment
Lane 7: lOuM 5azaC treatment
Lane 8: 3uM 5azaC treatment
Lane 9: luM 5azaC treatment
Lane 10: 3uM 5azaC treatment
Lane 11: 3uM BrdU treatment
Lane 12: DNA ladder

U.S. Patent

FIG.14

Dec. 9, 2014

Sheet 14of17

US 8,906,683 B2

U.S. Patent

FIG.15

Dec. 9, 2014

Sheet 15 of 17

US 8,906,683 B2

U.S. Patent

FIG. 16

Dec. 9, 2014

Sheet 16of17

US 8,906,683 B2

U.S. Patent

Dec. 9, 2014

Sheet 17 of 17

US 8,906,683 B2

N anog vector sequence analysis
ND

HD

_

FIG. 17

cm

CwD

C2D

.......
1111__
1111111------"--~

US 8,906,683 B2
1

2

METHODS AND MATERIALS FOR
INCREASING POTENCY OF CELLS

FIG. 8 shows images ofMeSC-derived neurons and astrocytes.
FIG. 9 shows sequence ofNanog encoding polynucleotide
and corresponding polypeptide sequence.
FIGS. 10-13 shows gel images of gene expression in cells
subjected to various treatments demonstrating an ability to
increase potency of mesenchymal stem cells and differentiation into cardiac cells.
FIGS. 14-16 show photograph images of cells subjected to
various treatments.
FIG. 17 shows a schematic representation of the nanog
sequence cloned inside a CMV mammalian promoter vector.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 11/258,401 filed Oct. 24, 2005, now issued as
U.S. Pat. No. 8,192,988; and which claims priority to U.S.
Provisional Application No. 60/621,901 filed Oct. 22, 2004
and 60/650,438 filed Feb. 4, 2005, both of which are incorporated herein in their entirety
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DETAILED DESCRIPTION

BACKGROUND OF THE INVENTION
15

The use of stem cells for the treatment of neurodegenerative conditions offers the hope of curing diseases like Alzheimer's and Parkinson's by means of transplantation [1]. However, major obstacles regarding cell procurement, directing
cell fate and avoiding immune response hinder clinical development [2-4] Research has focused on both adult and embryonic stem cells and attempted to balance limitations in regulating their development and preventing immune response.
Increased potency of stem cells can be achieved by epigenetic
modifications through nucleotide derivatives [5] and their
lineage can be directed by gene transfection [6, 7].
Patients currently suffering from neurodegenerative conditions have limited treatment options. Conventional drug
therapy helps delay or reduce the symptoms of disease but is
unable to restore complete functionality of the brain or repair
damaged tissue. Through stem cell-based therapies, scientists
aim to transplant cells in order to regenerate damaged tissue
and restore proper function. However, the best source of stem
cells for transplantation remains an unresolved issue; with
debate focusing around embryonic or adult derived stem
cells. Embryonic stem cells can be readily differentiated to
multiple neuronal fates but pose the risk of tumor formation
or immune response; whereas adult stem cell technology is
easily accessible, but provides limited capacity for transdifferentiation. An optimal approach may be to increase cellular
plasticity of adult stem cells for use in autologous transplantation.
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BRIEF DESCRIPTION OF THE DRAWINGS
45

FIG. 1 shows the vector system for cloning nanog according to the teachings in Example 1.
FIG. 2 shows images of cells before and after transfection
with nanog: A: shows mesenchymal stem cells pre-transfection; B: shows nanog-transfected mesenchymal stem cells 12
days post-cells 12 days post-transfection; C: shows nanogtransfected mesenchymal stem cells 4 weeks post-cells 4
weeks post-transfection.
FIG. 3 shows images of transfected mesenchymal stem
cells 9 days (A and B) and 2 months (C and D) post transfection.
FIG. 4 shows images a co-culture system in accord with
one embodiment of the subject invention.
FIG. 5 shows images of Co-culturing experiments which
demonstrated that embryoid body-like clusters began differentiation within 48 hours (A). Control cells with our empty
vector treatments failed to show any signs of neural differentiation (B). Embryoid-like bodies adhered to membrane and
differentiation occurred as neural cells migrated radially outward (C).
FIG. 6-7 show images of the clustering of nanog transfected cells.
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In reviewing the detailed disclosure which follows, and the
specification more generally, it should be borne in mind that
all patents, patent applications, patent publications, technical
publications, scientific publications, and other references referenced herein are hereby incorporated by reference in this
application, in their entirety to the extent not inconsistent with
the teachings herein.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art
would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.
The differentiation of stem cells along multiple lineages
has been intensely studied given their great therapeutic potential. However, the mechanisms that underlie proliferation,
self-renewal and differentiation in cells with the capacity for
further development remains poorly understood. A recently
discovered gene, nanog, is required to sustain pluripotency in
embryonic stem cells and acts concomitantly with embryonic
transcription factor Oct-4, yet utilizes a STAT-3 independent
mechanism. The subject invention is based on the inventor's
discovery that gene transfection of adult stem cells with
nanog, an embryonic stem cell gene maintaining pluripotency
[8,9], can allow for the production of neurons and astrocytes
from bone marrow cells via a two-step process. First, mesenchymal stem cells are modified by nanog transfection, and the
cells form embryoid-like bodies. Then cells are committed to
neuronal lineage in a co-culture system with differentiated
neural stem cells separated by a semi-permeable membrane.
This technology may be a means of generating effective
autologous stem cell transplants to improve neuroreplacement strategies. The inventors have discovered that adult stem
cells can be dedifferentiated through introduction and expression of the nanog gene or other dedifferentiating genes.
Thus, in one embodiment, the invention provides methods
for making a more developmentally potent cell from a less
developmentally potent cell. In a typical embodiment, the
method comprises the step of introducing an expressible

US 8,906,683 B2
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dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent
cell capable of differentiating to a less developmentally
potent cell of its lineage of origin or a different lineage. In
certain embodiments, the inventive methods further comprise
the step of co-culturing the transfected less developmentally
potent with neural-lineage cells or media conditioned with
neural-lineage cells, wherein the transfected cells become a
more developmentally potent cells capable of differentiating
to a less developmentally potent cells of its lineage of origin
or a different lineage.
In the practice of one embodiment of the invention, the
phenotype of the less developmentally potent cell is changed
when it becomes a more developmentally potent cell. Thus,
the invention provides methods for changing a first phenotype
of a less developmentally potent cell into a second phenotype
of more developmentally potent cell. The change from a
certain potency to a higher level of potency is considered
"dedifferentiation" in accord with the teachings herein. In
preferred embodiments, the less developmentally potent cell
is a stem cell, more preferably a hematopoietic stem cell, a
neural stem cell, an epithelial stem cell, an epidermal stem
cell, a retinal stem cell, an adipose stem cell and a mesenchymal stem cell.
In yet further aspects of the invention are provided pharmaceutical compositions comprising said more developmentally potent cells prepared according to the methods of the
invention and a pharmaceutically-acceptable carrier or
excipient. The invention provides such pharmaceutical compositions comprising said more developmentally potent cells
that are tissue stem cells for use in cell or tissue regeneration
or for correcting a disease or disorder in a tissue or animal in
need thereof.
Thus, the invention also provides methods for using the
pharmaceutical compositions provided herein to treat an animal in need thereof by administering the more developmentally potent cells thereto. In certain preferred embodiments,
the more developmentally potent cells comprise a cluster of
two or more of the more developmentally potent cells. Preferably, the animal has a corporal or neurological deficit that
can be treated or ameliorated by administration of said more
developmentally potent cells, such as a deficit caused by a
neurodegenerative disease, a traumatic injury, a neurotoxic
injury, ischemia, a developmental disorder, a disorder affecting vision, an injury or disease of the spinal cord, a demyelinating disease, an autoimmune disease, an infection, an
inflammatory disease, or corporal disease, disorder, injury,
trauma, malfunction, degeneration or loss. In preferred
embodiments, the one or plurality of more developmentally
potent cells are capable of migrating to an area of tissue
damage, differentiating in a tissue-specific manner and functioning in a manner that reduces the neurological or corporal
deficit. As provided by the methods of the invention herein,
the cells are administered by injecting one or a plurality of
more developmentally potent cells with a syringe, inserting
the more developmentally potent cells with a catheter or
surgically implanting the more developmentally potent cells.
In certain embodiments, the more developmentally potent
cells are injected with a syringe into a body cavity that is
fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. In other embodiments, the more developmentally potent cells are inserted with a catheter into a body cavity
that is fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity
is a brain ventricle. In still further additional embodiments,

the more developmentally potent cells are surgically
implanted into a body cavity that is fluidly-connected to the
area of neurological or corporal deficit. In certain preferred
embodiments, the body cavity is a brain ventricle. The more
developmentally potent cells can also alternatively be
inserted using a syringe or catheter or surgically implanted
directly at the site of the neurological or corporal deficit or
systemically (e.g., intravenously).
Also, the more developmentally potent cells may be further
genetically modified through introduction of polynucleotide
sequences the bias against differentiation to certain cell types
or bias toward differentiation to certain cell types. Provisional
Application Nos. 60/621,483 and 60/621,902 naming Dr.
Kiminobu Sugaya as an inventor and entitled "Methods and
Products For Biasing Development" are incorporated by reference to provide examples of negative and positive biasing
that could be subjected to the more developmentally potent
cells produced by the methods taught herein.
Administration of the one or a plurality of more developmentally potent cells into an animal results in said cells differentiating into a terminally-differentiated cell. Thus, the
invention provides methods for making a terminally-differentiated cell, comprising the step of administering the more
developmentally potent cells of the invention into an animal
in need thereof. As provided by the methods of the invention
herein, the cells are administered by injecting the more developmentally potent cells with a syringe, inserting the more
developmentally potent cells with a catheter or surgically
implanting the more developmentally potent cells. In certain
embodiments, the more developmentally potent cells are
injected with a syringe into a body cavity that is fluidlyconnected to the area of neurological or corporal deficit. In
certain preferred embodiments, the body cavity is a brain
ventricle. In other embodiments, the more developmentally
potent cells are inserted with a catheter into a body cavity that
is fluidly-connected to the area of neurological or corporal
deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. In still further additional embodiments, the
more developmentally potent cells are surgically implanted
into a body cavity that is fluidly-connected to the area of
neurological or corporal deficit. In certain preferred embodiments, the body cavity is a brain ventricle. The more developmentally potent cells can also alternatively be inserted
using a syringe or catheter or surgically implanted directly at
the site of the neurological or corporal deficit or systemically
(e.g., intravenously).
In yet another embodiment, the invention relates to treating
a stem cell, excluding those of neural origin, such that it is
converted into a more developmentally potent cell, which
enables it to differentiate into the various cell types found in
eye tissue, inter alia, chorid, Buchs and retinal pigment epithelium cells, rod and cone photoreceptor cells, horizontal
cells, bipolar neurons, amacrine, ganglion and optic nerve
cells. These non-limiting, exemplary cell types found in eye
tissue are collectively referred to as retinal cells. The methods
comprising the step of contacting more developmentally
potent cells of the invention with an effective amount of one
or a combination of growth factor selected from the group
consisting of TGF-b3, IGF-1 and CNTF for an effective
period such that the growth factor-contacted cells can differentiate into retinal cells.
As used herein, the terms "multipotent neural stem cells
(MNSCs )," "neural stem cells (NSCs )" and "neural progenitor cells (NPCs)" refer to undifferentiated, multipotent cells
of the CNS. Such terms are commonly used in the scientific
literature. MNSCs can differentiate into tissue-specific cell
types, for example astrocytes, oligodendrocytes, and neurons
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when transplanted in the brain. MNSCs of the invention are
distinguished from natural MNSCs by their adaptation for
proliferation, migration and differentiation in mammalian
host tissue when introduced thereto.
As used herein, a "less developmentally potent cell" is a
cell that is capable oflimited multi-lineage differentiation or
capable of single-lineage, tissue-specific differentiation, for
example, an untreated mesenchymal stem cell can differentiate into, inter alia, osteocytes and chrondrocytes, i.e., cells
of mesenchymal lineage, but has only limited ability to differentiate into cells of other lineages (e.g., neural lineage.).
As used herein, a "more developmentally potent cell" is a
cell that is readily capable of differentiating into a greater
variety of cell types than its corresponding less developmentally potent cell. For example, a mesenchymal stem cell can
readily differentiate into osteocytes and chrondrocytes but
has only limited ability to differentiate into neural or retinal
lineage cells (i.e., it is a less developmentally potent cell in
this context). Mesenchymal stem cells treated according to
the methods of the invention become more developmentally
potent because they can readily differentiate into, for
example, mesenchymal-lineage and neural-lineage cell
types; the plasticity of the cells is increased when treated
according to the methods of the invention.
The invention provides methods of delivery and transplantation of the more developmentally potent cells of the invention to ameliorate the effects of age, physical and biological
trauma and degenerative disease on the brain or central nervous system of an animal, as well as other tissues such as, for
example, retinal tissue. It is well recognized in the art that
transplantation of tissue into the CNS offers the potential for
treatment of neurodegenerative disorders and CNS damage
due to injury. Transplantation of new cells into the damaged
CNS has the potential to repair damaged circuitries and provide neurotransmitters thereby restoring neurological function. It is also recognized in the art that transplantation into
other tissue, such as eye tissue, offers the potential for treatment of degenerative disorders and tissue damage due to
injury. As disclosed herein, the invention provides methods
for generating more developmentally potent cells adapted for
proliferation, migration and differentiation in mammalian
tissue when introduced thereto. The use of more developmentally potent cells in the treatment of neurological disorders
and CNS damage, as well as the use of more developmentally
potent cells in the treatment of other tissue damage or degeneration, can be demonstrated by the use of established animal
models known in the art.
In one embodiment dedifferentiated cells or more developmentally potent cells of the invention can be administered
to an animal with abnormal or degenerative symptoms
obtained in any manner, including those obtained as a result
of age, physical or biological trauma, or neurodegenerative
disease and the like, or animal models created by man using
recombinant genetic techniques, such as transgenic and
"gene knockout" animals.
Recipients of the more developmentally potent cells of the
invention can be immunosuppressed, either through the use of
immunosuppressive drugs such as cyclosporin, or through
local immunosuppression strategies employing locally
applied immunosuppressants, but such immunosuppression
need not necessarily be a prerequisite in certain immunoprivileged tissues such as, for example, brain and eye tissues. In
certain embodiments, the delivery method of the invention
can cause less localized tissue damage to the site of cell
damage or malfunction than existing methods of delivery.
More developmentally potent cells of the invention can be
prepared from the recipient's own tissue. In such instances,

the progeny of the more developmentally potent cells can be
generated from dissociated or isolated tissue and proliferated
in vitro using the methods described herein. In the case of
mesenchymal stem cells (MeSCs ), progeny can be generated
from MeSCs isolated from, for example, bone marrow. Upon
suitable expansion of cell numbers, the stem cells of the
invention can be harvested and readied for administration into
the recipient's affected tissue.
There are significant differences in the method of delivery
to the brain of the more developmentally potent cells compared to the prior art. One exemplary difference is as follows:
the more developmentally potent cells of the invention are
transplanted intraventricularly. Further, while the transplantation of one or more separate more developmentally potent
cells is efficacious, the more developmentally potent cells of
the invention are preferably transplanted in the form of clusters of two or more cells via a surgical procedure or injection
using a syringe large enough to leave the clusters substantially intact. The results disclosed in the Examples below
indicate that ventricular delivery of more developmentally
potent cells of the invention in the form of a cluster of two or
more cells can result in migration to the area of damage in the
brain and proper neuronal differentiation. Another benefit of
intraventricular injection is less tissue destruction, resulting
in less localized recruitment of immune cells by the host. This
is evidenced by the lack of ventricular distortion, tumor formation, and increased host astrocyte staining without any
immunosuppression.
The method of delivery of the more developmentally
potent cells of the invention to the brain can be essentially
duplicated for other immunoprivileged tissue such as, for
example, the eye. Delivery of one or more separate or two or
more of the more developmentally potent cells in the form of
a cluster via injection using a syringe large enough to leave
the any cluster of two or more cells that is present substantially intact can result in migration to the area of damage in the
eye and proper tissue-specific differentiation.
In the context of the present application, a polynucleotide
sequence is "homologous" with the sequence according to the
invention if at least 70%, preferably at least 80%, most preferably at least 90% of its base composition and base sequence
corresponds to the sequence according to the invention.
According to the invention, a "homologous protein" is to be
understood to comprise proteins which contain an amino acid
sequence at least 70% of which, preferably at least 80% of
which, most preferably at least 90% of which, corresponds to
the amino acid sequence shown in FIG. 9; wherein corresponds is to be understood to mean that the corresponding
amino acids are either identical or are mutually homologous
amino acids. The expression "homologous amino acids"
denotes those which have corresponding properties, particularly with regard to their charge, hydrophobic character, steric
properties, etc. Thus, in one embodiment the protein may be
from 70% up to less than 100% homologous to nanog.
Homology, sequence similarity or sequence identity of
nucleotide or amino acid sequences may be determined conventionally by using known software or computer programs
such as the BestFit or Gap pairwise comparison programs
(GCG Wisconsin Package, Genetics Computer Group, 575
Science Drive, Madison, Wis. 53711). BestFit uses the local
homology algorithm of Smith and Waterman, Advances in
Applied Mathematics 2: 482-489 (1981), to find the best
segment of identity or similarity between two sequences. Gap
performs global alignments: all of one sequence with all of
another similar sequence using the method ofNeedleman and
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a
sequence alignment program such as BestFit, to determine
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the degree of sequence homology, similarity or identity, the
default setting may be used, or an appropriate scoring matrix
may be selected to optimize identity, similarity or homology
scores. Similarly, when using a program such as BestFit to
determine sequence identity, similarity or homology between
two different amino acid sequences, the default settings may
be used, or an appropriate scoring matrix, such as blosum45
or blosum80, may be selected to optimize identity, similarity
or homology scores.
The term "isolated" means separated from its natural environment.
The term "polynucleotide" refers in general to polyribonucleotides and polydeoxyribonucleotides, and can denote an
unmodified RNA or DNA or a modified RNA or DNA.
The term "polypeptides" is to be understood to mean peptides or proteins which contain two or more amino acids
which are bound via peptide bonds.
The polypeptides for use in accord with the teachings
herein include polypeptides corresponding to nanog, and also
includes those, at least 70% of which, preferably at least 80%
of which, are homologous with the polypeptide corresponding to nanog, and most preferably those which exhibit a
homology of least 90% to 95% with the polypeptide corresponding to nanog and which have dedifferentiating influence. See polypeptide sequence provided in FIG. 9. Thus, the
polypeptides may have a homology of from 70% to up to
100% with respect to nanog.
As used herein, a "polypeptide sequence exhibiting dedifferentiating influence" is a polypeptide whose presence in the
cell causes an increase in potency, or transformation from a
less developmentally potent cell to a more developmentally
potent cell. Examples of such polypeptide sequences include
the expression products of the nanog gene, and polynucleotide sequences that hybridize to the complement of the
sequence in FIG. 9, as well as expression products of the
polynucleotide sequences listed in Table 1 below in Example
3.
The terms "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which
a polynucleotide will hybridize to its target sequence, to a
detectably greater degree than other sequences (e.g., at least
2-fold over background). Stringent conditions are sequencedependent and will be different in different circumstances. By
controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are
100% complementary to the probe (homologous probing).
Alternatively, stringency conditions can be adjusted to allow
some mismatching in sequences so that lower degrees of
similarity are detected (heterologous probing).
Typically, stringent conditions will be those in which the
salt concentration is less than about 1.5 M Na ion, typically
about 0.01 to 1.0 MNa ion concentration (orother salts) at pH
7 .0 to 8.3 and the temperature is at least about 30° C. for short
probes (e.g., !Oto 50 nucleotides) and at least about 60° C. for
long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency
conditions include hybridization with a buffer solution of30
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl
sulphate) at 37° C., anda wash in lx to 2xSSC (20xSSC=3.0
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary
moderate stringency conditions include hybridization in 40 to
45%formamide, 1MNaCl,1%SDSat37°C.,andawashin
0.5x to lxSSC at 55 to 60° C. Exemplary high stringency
conditions include hybridization in 50% formamide, 1 M
NaCl, 1% SDS at 37° C., and a washinO.lxSSC at 60 to 65°
C.

Specificity is typically the function of post-hybridization
washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids,
the Tm can be approximated from the equation ofMeinkoth
and Wahl, Anal. Biochem., 138:267-284 (1984):
Tm=81.5oC.+16.6 (log M)+0.41 (% GC)-0.61 (% form)500/L; where Mis the molarity of monovalent cations, % GC
is the percentage of guano sine and cytosine nucleotides in the
DNA,% form is the percentage offormamide in the hybridization solution, and Lis the length of the hybrid in base pairs.
The Tm is the temperature (under defined ionic strength and
pH) at which 50% of a complementary target sequence
hybridizes to a perfectly matched probe. Tm is reduced by
about 1° C. for each 1% of mismatching; thus, Tm, hybridization and/or wash conditions can be adjusted to hybridize to
sequences of the desired identity. For example, if sequences
with approximately 90% identity are sought, the Tm can be
decreased 10° C. Generally, stringent conditions are selected
to be about 5° C. lower than the thermal melting point (Tm)
for the specific sequence and its complement at a defined
ionic strength and pH. However, severely stringent conditions
can utilize a hybridization and/or wash at 1, 2, 3, or 4° C.
lower than the thermal melting point (Tm); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7,
8, 9, or 10° C. lowerthan the thermal melting point (Tm); low
stringency conditions can utilize a hybridization and/or wash
at 11, 12, 13, 14, 15, or 20° C. lower than the thermal melting
point (Tm). Using the equation, hybridization and wash compositions, and desired Tm, those of ordinary skill will understand that variations in the stringency of hybridization and/or
wash solutions are inherently described. If the desired degree
of mismatching results in a Tm ofless than 45° C. (aqueous
solution) or 32° C. (formamide solution) it is preferred to
increase the SSC concentration so that a higher temperature
can be used. An extensive guide to the hybridization of
nucleic acids is found in Current Protocols in Molecular
Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing
and Wiley-Interscience, New York (2000).
Accordingly, polynucleotide sequences that hybridize to
the complement of the sequence in FIG. 9 are contemplated
for use in dedifferentiating cells as taught herein.
US. Patent Application Nos. 2003/0219898, 2003/
0148513, and 2003/0139410 are incorporated by reference to
the extent they are not inconsistent with the teachings herein.
These first two of these patent applications describe multiple
uses of increased potency cells obtained from the taught
methods, and in particular, the implantation of stem cells for
different therapeutic treatments of neurological trauma and
degenerative conditions. The third patent application is
directed to the use of certain compounds to stimulate proliferation and migration of stem cells. Those skilled in the art
will readily appreciate that the dedifferentiated cells of the
subject invention could be substituted in place of the potent
cells taught in the aforementioned patent applications, without undue experimentation. Also, the methods of the third
patent may be combined with the present invention without
undue experimentation.
According to another embodiment, the subject invention
comprises a method of influencing transcription of an endogenous polynucleotide sequence comprising contacting a nonembryonic cell or cellular component comprising an endogenous polynucleotide sequence with a nanog protein or
protein encoded by a polynucleotide sequence that hybridizes
to a complement of the sequence shown in FIG. 9 under
stringent conditions (i.e. nanog-like protein). Such influence
may further include, but is not limited to, demethylation of
DNA and reversal histone acetylation. The nanog protein or
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nanog-like protein may be one expressed by a polynucleotide
sequence introduced in the cell or cellular component, or
protein delivered into the cell or cellular component, or protein expressed by an endogenous polynucleotide sequence
that has been activated. Nanog expression may be activated
by the provision of Oct 4 and/or Sox2, which typically form
a dimer. In a specific embodiment, the cellular component is
a nucleus, liposome, or mitochondria. Such endogenous
polynucleotide sequence or cellular component contacted by
nanog or nanog may be removed from a cell or cellular
component and introduced into another cell or cellular component.
In another specific embodiment, the invention pertains to
increasing the efficacy of nuclear transfer comprising transfecting a nucleus with a polynucleotide encoding nanog or
nanog-like protein to obtain a treated nucleus and introducing
the treated nucleus into a cell. The cell may be any suitable
cell but would typically be an ovum with its nucleus removed.

studies have shown evidence that adult stem cells can migrate
and differentiate into various tissues, albeit at extremely low
frequencies [20]. However, challenges have been raised over
the plasticity of these cells given both the low frequencies of
detected cells and new found evidence of cell fusion, in conjunction with false positives [25-27]. An ideal therapeutic
alternative may exist if adult cells can be dedifferentiated to
an embryonic-like state and recommitted to differentiate to a
desired cell fate.
Nanog, also referred to as early embryo specific NK (ENK)
[28], is a recently discovered gene responsible for maintaining pluripotency in embryonic stem cells [8, 9, 28, 29]. This
unique gene and its cousin, Nanog2, are genetically distinct
members of the ANTP class of homeodomain proteins [30]
and have at least twelve identified pseudogenes [31]. Structurally, Nanog contains three alpha helixes encoded within
the homeodomain portion and can be divided into three
regions with respect to the central homeodomain sequence
[30]. The N-terminal region is rich in serine and threonine
residues indicating phosphate-regulated transactivation, possibly through SMAD4 interactions, while the C-terminal
domain is seven times as active with an unusual motif of
equally spaced tryptophans separated by four amino acids,
each flanked with serine or threonine residues. Gene expression studies have shown nanog to be active in embryonic stem
cells, tumors and some adult tissue. Nanog expression precipitously decreases with differentiation and maintains selfrenewal in embryonic stem cells by gene transfection. In
culture, nanog guards against differentiation and acts concomitantly with Oct-4, Wnt and BMP-4, yet utilizes a STAT-3
independent mechanism to maintain an undifferentiated
state. Inventors believe that the role of nanog in regulating
pluripotency makes this gene a potential candidate for
increasing the potency of adult stem cells.
Previous studies regulating gene expression in stem cell
lines have provided valuable insight into underlying mechanisms of proliferation, self-renewal and differentiation. Gene
manipulation experiments can either prevent or enhance differentiation. In particular, differentiation can be prevented in
embryonic stem cell lines by over expression of Pem or
nanog, genes that regulate pluripotency. Conversely, overexpression of lineage specific gene Nurrl promotes the differentiation of neura 1 stem cell lines to produce dopaminesecreting cells. Taken together, gene vectors can maintain
cells in a specific state or allow for lineage committed cells to
develop into a specific subpopulation. In one embodiment,
the subject invention pertains to a method of dedifferentiating
adult stem cells by expressing genes regulating pluripotency
to enhance transdifferentiation. This technology allows for
adult cells to be used for autologous transplantation and
thereby provide a greater understanding of stem cell biology.
FIG. 17 shows a schematic representation of the nanog
sequence cloned inside a CMV mammalian promoter vector.
The 5'UTR contains an Oct-4 and Sox2 binding region. The
nanog protein coding sequence can be divided into an N-terminal, homeodomain and C-terminal region. The C-terminal
region can be further subdivided into a Cl, Cw and C2
domains. The 3' UTR contains an Alu sequence element.
Methods and Results
Human mesenchymal stem cells (hMeSC) are initially
plated in 6-well plates, adhere to the surface and allowed to
divide to varying degrees of confluence. They are cultured in
serum-DMEM (Dulbecco's modified Eagle's medium) containing 10% FCS, 5% HS, 292 mg/ml glutamine, 50 U/ml
streptomycin and penicillin (all from Invitrogen).
Cloning of nanog was achieved by first performing polymerase chain reaction with primers corresponding to the

Example 1

10

15

20

Dedifferentiation ofMesenchymal Stem Cells
Introduction
Embryonic stem cells are derived during the blastocyst
stage from the inner cell mass of prenatal mammalia; and
possess the intrinsic properties of rapid self-renewal and
pluripotency. Under the influence of endogenous and extracellular signals, these cells migrate and differentiate during
the developmental process. Extracellular signals regulating
self-renewal or differentiation have been demonstrated in
vitro by differentiating embryonic stem cells into cell types
comprising all three germ layers. These varieties include
neuronal, pancreatic, cardiac and hematopoietic tissue using
well-established culturing protocols. Embryonic stem cells
form embryoid bodies, non-adherent proliferating clusters, in
the presence ofleukemia-inhibitory factor (LIF) and a feeder
layer of typically fibroblast cells. Upon removal of LIF or
transfer to non-feeder cell cultures, embryoid bodies undergo
spontaneous differentiation. Early differentiation is characterized by loss of stem cell-specific surface antigens (SSEA1) and alkaline phosphatase activity. Additionally, endogenous signals, including regulatory intracellular proteins,
continually change throughout development. Numerous gene
expression studies show distinct variations among different
embryonic and adult stem cells, pointing toward underlying
mechanisms responsible for the continual loss of potency
corresponding with differentiation. Several key genes,
namely Oct-3/4, LIF, DNMT3B and Nanog, are repeatedly
shown to be almost exclusively expressed in embryonic stem
cells that regulate pluripotency [10-14]. The immediate
down-regulation of these genes may explain irreversible loss
of potency, making embryonic stem cells an attractive source
for clinical therapies. However, serious questions remain concerning the production of these cells in sufficient quantities
for therapies, bioethical potential immune response and
tumor formation [15].
The inventors believe that adult stem cells offer a practicable alternative to the use of embryonic tissue as they are
easily harvested and potentially taken from autologous
sources to preclude immune response. Stem cell populations
have been found in several adult tissues including adipose
[16], muscle [17], pancrease [18] and liver [19] and primarily
bone marrow [20-23]; all potential sources for cellular transplants [24]. Previous in vitro studies with adult bone marrowderived stem cells have demonstrated the ability to differentiate into brain [21], liver [23] and cardiac cells [22]. In vivo
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nanog gene family (5'-tttttcctcctcttcctcta-3', SEQ ID NO. 3,
and 5'-attggtgatgaagatgtatt-3' SEQ ID NO. 4) against a
human genome DNA template. The PCR product was cloned
into pcDNA Hismax TOPO TA cloning mammalian expression vector (Invitrogen) and inserted in E coli. See FIG. 1.
Bacterial cells were plated on agar plates containing LB agar
and ampacillin and incubated overnight at 37° C. Isolated
colonies were transferred to growth media and grown overnight in a 37° C. rotating at 200 rpm. Plasmid isolation was
performed using endotoxin free maxiprep (Beckon Dickenson) or miniprep kits (Clonetech). Gene segment was then
confirmed by gel electrophoresis through enzyme digestion
and DNA sequencing. The gene product was approximately
1600 base pairs, consistent with the nanog gene. However,
sequencing analysis matched nanog pseudogene 8
(NANOG8), a segment containing no intrans and sharing 99
percent homology with nanog. See. The deduced protein
product is almost identical with two differing amino acids.
The gene product encodes for a nanog-like protein with a 305
amino acid serine/threonine-rich sequence. The protein can
be divided into three distinct domains at the N-terminal,
homeodomain and C-terminal as previously described.
Upon reaching a desired cell number, approximately 75%
confluence, HMeSCs were transfected with above-mentioned vector using NeuroPorter (Gene Therapy System)
transfection system. Concentrations of NeuroPorter and
DNA (0.5 µg/ml to 40 µg/ml) were varied to achieve optimal
results. Cells became non-adherent and began to multiply,
forming spherical clusters: consistent with embryoid body
formation. Thus, they achieved characteristics of embryonic
stem cells.
Nanog transfection of mesenchymal stem cells resulted in
morphological changes similar to embryoid body formation
(FIG. 2-4). Cellular transformation occurred in a pattern of
transfection, non-adherence, survival and proliferation. Nonadherent clusters proliferated in vitro beyond two months in
the presence of remaining adherent mesenchymal stem cells.
To determine if nanog could restore pluripotency in adult
cells rather than simply maintain the state in embryonic cells,
the inventors developed a two-step process of dedifferentiation and development along an alternative lineage, discussed
in Example 2 below. Human mesenchymal stem cells were
cultured in a six-well culture plates and were allowed to
adhere and grow for at least 48 hours to achieve approximately 7 5% confluence. Cells were subsequently transfected
with a mammalian cell vector or control vehicle, cultured and
examined. Cells transfected with NANOGP8 became nonadherent and proliferated in the presence of the remaining
adherent cells acting as a feeder layer. Control samples
receiving empty transfection did not show any proliferation
and decreased dramatically, likely due to the toxicity of the
transfection. Transferring non-adherent cells to wells without
a feeder layer resulted in apoptosis, related to either absence
of feeder cell proteins of decreased cell density. Cellular
transformation occurred in a pattern of transfection, nonadherence, survival and proliferation. Transformed cells proliferated in three-dimensional clusters for months in culture.
These characteristics are similar to embryonic stem cells.

formed mesenchymal cells. Neural stem cells spheres were
placed in 12 well plates and differentiated using serum-free
basal media as previously described. Neuronal stem cells
began to differentiate by becoming adherent and migrating
radially outwards from the original neural sphere. Following
neural stem cell differentiation, these cells were utilized as
feeder cells in our co-culture system by placing modified cells
inside co-culture chamber that separated modified stem cells
from the feeder layer with a 0.2 µm semipermeable membrane. See FIG. 5. Within 48 hours, transferred cells began to
display characteristics of differentiation marked by morphological alterations, membrane adherence and outward migration. FIG. 6. Immunohistochemical analysis revealed positive
markers for ~ -III tubulin and GFAP, showing neuron and glial
differentiation. Positive staining for mixed neuronal populations was observed in non-adherent clusters cultured for more
than 48 hours, adherent cell masses and individual membrane
bound cells.
Co-culturing experiments showed embryoid body-like
clusters began differentiation within 48 hours. Control cells
with our vector treatments failed to show any signs of neural
differentiation. Immunohistochemical staining revealed
nanog transfected samples intensely stained positive for ~IIItubulin and GFAP, indicating neuron and astrocyte differentiation. See FIGS. 6-7. Originally, nanog-transformed cells
remain in a cluster of differentiating neural cells that continually radiate outward (See FIGS. 6- 7). FIG. 8 shows MeSC
derived neurons and astrocytes.
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Neuronal Differentiation of Dedifferentiated
Mesenchymal Cells
To test whether cells can be dedifferentiated using nanog
and committed to an alternate lineage we utilized a co-culture
system of differentiated human neural stem cells and trans-

Following the transfection and evaluation protocol provided above in Example 1, PCR products of the genes in Table
1 are evaluated for their ability to dedifferentiate cells, particularly mesenchymal stem cells.
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Pem (mouse GI: 1255173)
Fan Y, et al. Developmental Biology 210: 481-496. 1999
POU5Fl (Unigene Hs.2860)
Sox2 (Unigene Hs.816)
HESXl (Unigene Hs.171980)
UTFl (Unigene Hs.158307)
REX! (Unigene Hs.335787)
FOXD3 (Unigene Hs.120204)
GBX2 (Unigene Hs.326290)
NANOG (Unigene Hs.326290)
LIN-28 (Unigene 86154)
TGIF
DNMT3A/B (251673)
TGFFl (75561)
Richards M, et al. Stem Cells 22: 51-64. 2004
EGS-1 (accession# X57708.1)
FGF4 Tanaka T, et al. Genone Research 12: 1921-1928. 2002.
Rex-1 (accession #AF450454)
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derivatives BrdU and 5-azaC and/or forced expression of
embryonic stem cell gene nanog. Following treatment, cells
were placed in a co-culture with cardiac cells (cardiomyocyte
cell line H9c2). Human MeSCs plated in 6-well culture plates
and expanded in serum-DMEM (Delbecco's Modified
Eagle's Medium) containing 10% MeSC formulated fetal
bovine serum (FBS, Stem Cell, Inc) containing antibiotics/
antimycotics. MeSCs were treated with varying concentrations (1-10 uM) of BrdU and/or 5-azaC for 3 weeks or transfected with mammalian expression vector containing a nanog
encoding sequence. Cell media was changed every three days
prior to co-culture with cardiomyocytes. Cardiomyocytes
were expanded and grown to near confluence in serumDMEM with 10% non-conditioned FBS and antibiotics/antimycotics. To differentiate cardiac cells, serum media was
replaced with plain DMEM containing only antibiotics and
allowed to differentiate. Co-cultures were created by combining MeSCs with cardiac cells and culturing in cardiac media.
Following co-culture, cells were treated with TRizol and gene
expression was assessed using RT-PCR and cardiac specific
primers. Gel electrophoresis of samples revealed expression
of cardiac specific genes following treatment.
The first (Electrophoresis 050101, FIG.10) shows screens
for each primer tested. The key shows which sample is in a
given lane. Negative control represents untreated mesenchyma! stem cells and Positive controls 1x and 2x are nanog
transfected MeSCs (2x indicates that well received twice the
number of rat cardiac cells, not twice the amount of nanog
transfected cells). Each sample was co-cultured with rat car-

diomyocytes and primers are human specific and represent
markers of cardiomyocyte related gene expression. The second data set (Electrophoresis 050115, FIG. 11) shows gene
expression for each primer following 3 uM treatment of either
BrdU or SazaC. The high and low RNA is because we had low
cell numbers and tested one well (low RNA) against combining two wells of equal treatment (high RNA). The third
attachment (Electrophoresis 050116, FIG. 12) shows the
effects of three weeks treatment of combined (3 uM or 1 uM
of both SazaC and BrdU), 3 uM of either SazaC or BrdU, or
nanog transfected cells (marked "control"). The poor quality
is the result of low cell numbers and the use of a different
RT-PCR kit (BioRad instead of the usual Invitrogen). See also
FIG. 13. FI GS. 14-16 pertain to photograph images ofMeSCs
treated with 3 uM ofSazaC (A 050123 3 uM SazaC 3 weeks
MSC.jpg, FIG. 14), of3 uM ofBrdU (A 050123 3 uM BrdU
3 weeks MSC.jpg, FIG. 15) and of nanog transfected cells
combined with rat cardiac cells in co-culture (A 41227 of
ntMSC 1213 2.jpg, FIG. 16). The cell differentiation is due to
environmental signals and cell to cell contacts.
The inventors demonstrate that treatment with nucleotide
derivatives and/or nanog transfection provides for cardiac
differentiation of mesenchymal stem cells. Accordingly, an
embodiment of the invention pertains to a method of increasing the potency of a cell comprising introducing a gene comprising nanog activity, optionally in conjunction with treatment of such cell with a compound, such as a nucleotide
derivative, known to exert a dedifferentiating influence on
cells.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>
<220>
<221>
<222>

9

SEQ ID NO 1
LENGTH, 1628
TYPE, DNA
ORGANISM, Homo sapiens
FEATURE,
NAME/KEY, CDS
LOCATION, (28) .. (945)

<400> SEQUENCE,

1

tttttcctcc tcttcctcta tactaac atg agt gtg gat cca get tgt CCC caa

54

Met Ser Val Asp Pro Ala Cys Pro Gln
1

5

age ttg cct tgc ttt gaa gaa tee gac tgt aaa gaa tct tea cct atg
Ser Leu Pro Cys Phe Glu Glu Ser Asp Cys Lys Glu Ser Ser Pro Met
10

15

20

25

cct gtg att tgt ggg cct gaa gaa aac tat cca tee ttg caa atg tct
Pro Val Ile Cys Gly Pro Glu Glu Asn Tyr Pro Ser Leu Gln Met Ser
30

35

50

65

80

95

294

85

aag gtc ccg gtc aag aaa cag aag ace aga act gtg ttc tct tee ace
Lys Val Pro Val Lys Lys Gln Lys Thr Arg Thr Val Phe Ser Ser Thr
90

246

70

ggc aaa caa CCC act tct gca gag aat agt gtc gca aaa aag gaa gac
Gly Lys Gln Pro Thr Ser Ala Glu Asn Ser Val Ala Lys Lys Glu Asp
75

198

55

atg gat ctg ctt att cag gac age cct gat tct tee ace agt CCC aaa
Met Asp Leu Leu Ile Gln Asp Ser Pro Asp Ser Ser Thr Ser Pro Lys
60

150

40

tct get gag atg cct cac aca gag act gtc tct cct ctt cct tee tee
Ser Ala Glu Met Pro His Thr Glu Thr Val Ser Pro Leu Pro Ser Ser
45

102

100

342

105

cag ctg tgt gta etc aat gat aga ttt cag aga cag aaa tac etc age

390
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Gln Leu Cys Val Leu Asn Asp Arg Phe Gln Arg Gln Lys Tyr Leu Ser
110
115
120
etc cag cag atg caa gaa etc tee aac ate ctg aac etc age tac aaa
Leu Gln Gln Met Gln Glu Leu Ser Asn Ile Leu Asn Leu Ser Tyr Lys
125
130
135

438

cag gtg aag ace tgg ttc cag aac cag aga atg aaa tct aag agg tgg
Gln Val Lys Thr Trp Phe Gln Asn Gln Arg Met Lys Ser Lys Arg Trp
140
145
150

486

cag aaa aac aac tgg ccg aag aat age aat ggt gtg acg cag aag gee
Gln Lys Asn Asn Trp Pro Lys Asn Ser Asn Gly Val Thr Gln Lys Ala
155
160
165

534

tea gca cct ace tac ccc age etc tac tct tee tac cac cag gga tgc
Ser Ala Pro Thr Tyr Pro Ser Leu Tyr Ser Ser Tyr His Gln Gly Cys
170
175
180
185

582

ctg gtg aac ccg act ggg aac ctt cca atg tgg age aac cag ace tgg
Leu Val Asn Pro Thr Gly Asn Leu Pro Met Trp Ser Asn Gln Thr Trp
190
195
200

630

aac aat tea ace tgg age aac cag ace cag aac ate cag tee tgg age
Asn Asn Ser Thr Trp Ser Asn Gln Thr Gln Asn Ile Gln Ser Trp Ser
205
210
215

678

aac cac tee tgg aac act cag ace tgg tgc ace caa tee tgg aac aat
Asn His Ser Trp Asn Thr Gln Thr Trp Cys Thr Gln Ser Trp Asn Asn
220
225
230

726

cag gee tgg aac agt ccc ttc tat aac tgt gga gag gaa tct ctg cag
Gln Ala Trp Asn Ser Pro Phe Tyr Asn Cys Gly Glu Glu Ser Leu Gln
235
240
245

774

tee tgc atg cac ttc cag cca aat tct cct gee agt gac ttg gag get
Ser Cys Met His Phe Gln Pro Asn Ser Pro Ala Ser Asp Leu Glu Ala
250
255
260
265

822

gee ttg gaa get get ggg gaa ggc ctt aat gta ata cag cag ace act
Ala Leu Glu Ala Ala Gly Glu Gly Leu Asn Val Ile Gln Gln Thr Thr
270
275
280

870

agg tat t t t agt act cca caa ace atg gat tta ttc eta aac tac tee
Arg Tyr Phe Ser Thr Pro Gln Thr Met Asp Leu Phe Leu Asn Tyr Ser
285
290
295

918

atg aac atg caa cct gaa gac gtg tga agatgagtga aactgatatt
Met Asn Met Gln Pro Glu Asp Val
300
305

965

actcaatttc agtctggaca ctggctgaat ccttcctctc ccctcctccc atccctcata

1025

ggatttttct tgtttggaaa ccacgtgttc tggtttccat gatgcctatc cagtcaatct

1085

catggagggt ggagtatggt tggagcctaa tcagcgaggt ttcttttttt ttttttccta

1145

ttggatcttc ctggagaaaa tacttttttt tttttttttg agacggagtc ttgctctgtc

1205

gcccaggctg gagtgcagtg gcgcggtctt ggctcactgc aagctccgcc tcccgggttc

1265

acgccattct cctgcctcag cctcccgagc agctgggact acaggcgccc gccacctcgc

1325

ccggctaata ttttgtattt ttagtagaga cagggtttca ctgtgttagc caggatggtc

1385

tcgatctcct gaccttgtga tccgcccgcc tcggcctccc taacagctgg gattacaggc

1445

gtgagccacc gcgccctgcc tagaaaagac attttaataa ccttggctgc taaggacaac

1505

attgatagaa gccgtctctg gctatagata agtagatcta atactagttt ggatatcttt

1565

agggtttaga atctaacctc aagaataaga aatacaagta cgaattggtg atgaagatgt

1625

att

1628

<210> SEQ ID NO 2
<211> LENGTH, 305
<212> TYPE, PRT
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<213> ORGANISM, Homo sapiens
<400> SEQUENCE, 2
Met Ser Val Asp Pro Ala Cys Pro Gln Ser Leu Pro Cys Phe Glu Glu
1
5
10
15
Ser Asp Cys Lys Glu Ser Ser Pro Met Pro Val Ile Cys Gly Pro Glu
20
25
30
Glu Asn Tyr Pro Ser Leu Gln Met Ser Ser Ala Glu Met Pro His Thr
35
40
45
Glu Thr Val Ser Pro Leu Pro Ser Ser Met Asp Leu Leu Ile Gln Asp
50
55
60
Ser Pro Asp Ser Ser Thr Ser Pro Lys Gly Lys Gln Pro Thr Ser Ala
65
70
75
80
Glu Asn Ser Val Ala Lys Lys Glu Asp Lys Val Pro Val Lys Lys Gln
85
90
95
Lys Thr Arg Thr Val Phe Ser Ser Thr Gln Leu Cys Val Leu Asn Asp
100
105
110
Arg Phe Gln Arg Gln Lys Tyr Leu Ser Leu Gln Gln Met Gln Glu Leu
115
120
125
Ser Asn Ile Leu Asn Leu Ser Tyr Lys Gln Val Lys Thr Trp Phe Gln
130
135
140
Asn Gln Arg Met Lys Ser Lys Arg Trp Gln Lys Asn Asn Trp Pro Lys
145
150
155
160
Asn Ser Asn Gly Val Thr Gln Lys Ala Ser Ala Pro Thr Tyr Pro Ser
165
170
175
Leu Tyr Ser Ser Tyr His Gln Gly Cys Leu Val Asn Pro Thr Gly Asn
180
185
190
Leu Pro Met Trp Ser Asn Gln Thr Trp Asn Asn Ser Thr Trp Ser Asn
195
200
205

Gln Thr Gln Asn Ile Gln Ser Trp Ser Asn His Ser Trp Asn Thr Gln
210
215
220
Thr Trp Cys Thr Gln Ser Trp Asn Asn Gln Ala Trp Asn Ser Pro Phe
225
230
235
240
Tyr Asn Cys Gly Glu Glu Ser Leu Gln Ser Cys Met His Phe Gln Pro
245
250
255
Asn Ser Pro Ala Ser Asp Leu Glu Ala Ala Leu Glu Ala Ala Gly Glu

260

265

270

Gly Leu Asn Val Ile Gln Gln Thr Thr Arg Tyr Phe Ser Thr Pro Gln
275
280
285
Thr Met Asp Leu Phe Leu Asn Tyr Ser Met Asn Met Gln Pro Glu Asp
290
295
300
Val
305

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
tttttcctcc tcttcctcta

<210> SEQ ID NO 4

20
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<211>
<212>
<213>
<220>
<223>

LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 4
attggtgatg aagatgtatt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 5
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
6 His Tag

<400> SEQUENCE, 5
His His His His His His
5

1

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 1417
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 4
tcccttcgca agccctcatt tcaccaggcc cccggcttgg ggcgccttcc ttccccatgg

60

cgggacacct ggcttcggat ttcgccttct cgccccctcc aggtggtgga ggtgatgggc

120

caggggggcc ggagccgggc tgggttgatc ctcggacctg gctaagcttc caaggccctc

180

ctggagggcc aggaatcggg ccgggggttg ggccaggctc tgaggtgtgg gggattcccc

240

catgcccccc gccgtatgag ttctgtgggg ggatggcgta ctgtgggccc caggttggag

300

tggggctagt gccccaaggc ggcttggaga cctctcagcc tgagggcgaa gcaggagtcg

360

gggtggagag caactccgat ggggcctccc cggagccctg caccgtcacc cctggtgccg

420

tgaagctgga gaaggagaag ctggagcaaa acccggagga gtcccaggac atcaaagctc

480

tgcagaaaga actcgagcaa tttgccaagc tcctgaagca gaagaggatc accctgggat

540

atacacaggc cgatgtgggg ctcaccctgg gggttctatt tgggaaggta ttcagccaaa

600

cgaccatctg ccgctttgag gctctgcagc ttagcttcaa gaacatgtgt aagctgcggc

660

ccttgctgca gaagtgggtg gaggaagctg acaacaatga aaatcttcag gagatatgca

720

aagcagaaac cctcgtgcag gcccgaaaga gaaagcgaac cagtatcgag aaccgagtga

780

gaggcaacct ggagaatttg ttcctgcagt gcccgaaacc cacactgcag cagatcagcc

840

acatcgccca gcagcttggg ctcgagaagg atgtggtccg agtgtggttc tgtaaccggc

900

gccagaaggg caagcgatca agcagcgact atgcacaacg agaggatttt gaggctgctg

960

ggtctccttt ctcaggggga ccagtgtcct ttcctctggc cccagggccc cattttggta

1020

ccccaggcta tgggagccct cacttcactg cactgtactc ctcggtccct ttccctgagg

1080

gggaagcctt tccccctgtc tccgtcacca ctctgggctc tcccatgcat tcaaactgag

1140

gtgcctgccc ttctaggaat gggggacagg gggaggggag gagctaggga aagaaaacct

1200

ggagtttgtg ccagggtttt tgggattaag ttcttcattc actaaggaag gaattgggaa

1260

cacaaagggt gggggcaggg gagtttgggg caactggttg gagggaaggt gaagttcaat

1320

gatgctcttg attttaatcc cacatcatgt atcacttttt tcttaaataa agaagcctgg

1380
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gacacagtaa aaaaaaaaaa aaaaaaaaaa aaaaaaa

<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 360
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 7
Met Ala Gly His Leu Ala Ser Asp Phe Ala Phe Ser Pro Pro Pro Gly
1
5
10
15
Gly Gly Gly Asp Gly Pro Gly Gly Pro Glu Pro Gly Trp Val Asp Pro
20
25
30
Arg Thr Trp Leu Ser Phe Gln Gly Pro Pro Gly Gly Pro Gly Ile Gly
35
40
45
Pro Gly Val Gly Pro Gly Ser Glu Val Trp Gly Ile Pro Pro Cys Pro
50
55
60
Pro Pro Tyr Glu Phe Cys Gly Gly Met Ala Tyr Cys Gly Pro Gln Val
65
70
75
80
Gly Val Gly Leu Val Pro Gln Gly Gly Leu Glu Thr Ser Gln Pro Glu
85
90
95
Gly Glu Ala Gly Val Gly Val Glu Ser Asn Ser Asp Gly Ala Ser Pro
100
105
110
Glu Pro Cys Thr Val Thr Pro Gly Ala Val Lys Leu Glu Lys Glu Lys
115
120
125
Leu Glu Gln Asn Pro Glu Glu Ser Gln Asp Ile Lys Ala Leu Gln Lys
130
135
140
Glu Leu Glu Gln Phe Ala Lys Leu Leu Lys Gln Lys Arg Ile Thr Leu
145
150
155
160
Gly Tyr Thr Gln Ala Asp Val Gly Leu Thr Leu Gly Val Leu Phe Gly
165
170
175
Lys Val Phe Ser Gln Thr Thr Ile Cys Arg Phe Glu Ala Leu Gln Leu
180
185
190
Ser Phe Lys Asn Met Cys Lys Leu Arg Pro Leu Leu Gln Lys Trp Val
195
200
205
Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln Glu Ile Cys Lys Ala Glu
210
215
220
Thr Leu Val Gln Ala Arg Lys Arg Lys Arg Thr Ser Ile Glu Asn Arg
225
230
235
240
Val Arg Gly Asn Leu Glu Asn Leu Phe Leu Gln Cys Pro Lys Pro Thr
245
250
255
Leu Gln Gln Ile Ser His Ile Ala Gln Gln Leu Gly Leu Glu Lys Asp
260
265
270
Val Val Arg Val Trp Phe Cys Asn Arg Arg Gln Lys Gly Lys Arg Ser
275
280
285
Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe Glu Ala Ala Gly Ser Pro
290
295
300
Phe Ser Gly Gly Pro Val Ser Phe Pro Leu Ala Pro Gly Pro His Phe
305
310
315
320
Gly Thr Pro Gly Tyr Gly Ser Pro His Phe Thr Ala Leu Tyr Ser Ser
325
330
335
Val Pro Phe Pro Glu Gly Glu Ala Phe Pro Pro Val Ser Val Thr Thr
340
345
350
Leu Gly Ser Pro Met His Ser Asn

355

360

1417
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<210>
<211>
<212>
<213>

SEQ ID NO 8
LENGTH, 2518
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 8

ctattaactt gttcaaaaaa gtatcaggag ttgtcaaggc agagaagaga gtgtttgcaa

60

aagggggaaa gtagtttgct gcctctttaa gactaggact gagagaaaga agaggagaga

120

gaaagaaagg gagagaagtt tgagccccag gcttaagcct ttccaaaaaa taataataac

180

aatcatcggc ggcggcagga tcggccagag gaggagggaa gcgctttttt tgatcctgat

240

tccagtttgc ctctctcttt ttttccccca aattattctt cgcctgattt tcctcgcgga

300

gccctgcgct cccgacaccc ccgcccgcct cccctcctcc tctccccccg cccgcgggcc

360

ccccaaagtc ccggccgggc cgagggtcgg cggccgccgg cgggccgggc ccgcgcacag

420

cgcccgcatg tacaacatga tggagacgga gctgaagccg ccgggcccgc agcaaacttc

480

ggggggcggc ggcggcaact ccaccgcggc ggcggccggc ggcaaccaga aaaacagccc

540

ggaccgcgtc aagcggccca tgaatgcctt catggtgtgg tcccgcgggc agcggcgcaa

600

gatggcccag gagaacccca agatgcacaa ctcggagatc agcaagcgcc tgggcgccga

660

gtggaaactt ttgtcggaga cggagaagcg gccgttcatc gacgaggcta agcggctgcg

720

agcgctgcac atgaaggagc acccggatta taaataccgg ccccggcgga aaaccaagac

780

gctcatgaag aaggataagt acacgctgcc cggcgggctg ctggcccccg gcggcaatag

840

catggcgagc ggggtcgggg tgggcgccgg cctgggcgcg ggcgtgaacc agcgcatgga

900

cagttacgcg cacatgaacg gctggagcaa cggcagctac agcatgatgc aggaccagct

960

gggctacccg cagcacccgg gcctcaatgc gcacggcgca gcgcagatgc agcccatgca

1020

ccgctacgac gtgagcgccc tgcagtacaa ctccatgacc agctcgcaga cctacatgaa

1080

cggctcgccc acctacagca tgtcctactc gcagcagggc acccctggca tggctcttgg

1140

ctccatgggt tcggtggtca agtccgaggc cagctccagc ccccctgtgg ttacctcttc

1200

ctcccactcc agggcgccct gccaggccgg ggacctccgg gacatgatca gcatgtatct

1260

ccccggcgcc gaggtgccgg aacccgccgc ccccagcaga cttcacatgt cccagcacta

1320

ccagagcggc ccggtgcccg gcacggccat taacggcaca ctgcccctct cacacatgtg

1380

agggccggac agcgaactgg aggggggaga aattttcaaa gaaaaacgag ggaaatggga

1440

ggggtgcaaa agaggagagt aagaaacagc atggagaaaa cccggtacgc tcaaaaagaa

1500

aaaggaaaaa aaaaaatccc atcacccaca gcaaatgaca gctgcaaaag agaacaccaa

1560

tcccatccac actcacgcaa aaaccgcgat gccgacaaga aaacttttat gagagagatc

1620

ctggacttct ttttggggga ctatttttgt acagagaaaa cctggggagg gtggggaggg

1680

cgggggaatg gaccttgtat agatctggag gaaagaaagc tacgaaaaac tttttaaaag

1740

ttctagtggt acggtaggag ctttgcagga agtttgcaaa agtctttacc aataatattt

1800

agagctagtc tccaagcgac gaaaaaaatg ttttaatatt tgcaagcaac ttttgtacag

1860

tatttatcga gataaacatg gcaatcaaaa tgtccattgt ttataagctg agaatttgcc

1920

aatatttttc aaggagaggc ttcttgctga attttgattc tgcagctgaa atttaggaca

1980

gttgcaaacg tgaaaagaag aaaattattc aaatttggac attttaattg tttaaaaatt

2040

gtacaaaagg aaaaaattag aataagtact ggcgaaccat ctctgtggtc ttgtttaaaa

2100

agggcaaaag ttttagactg tactaaattt tataacttac tgttaaaagc aaaaatggcc

2160

US 8,906,683 B2
27

28
-continued

atgcaggttg acaccgttgg taatttataa tagcttttgt tcgatcccaa ctttccattt

2220

tgttcagata aaaaaaacca tgaaattact gtgtttgaaa tattttctta tggtttgtaa

2280

tatttctgta aatttattgt gatattttaa ggttttcccc cctttatttt ccgtagttgt

2340

attttaaaag attcggctct gtattatttg aatcagtctg ccgagaatcc atgtatatat

2400

ttgaactaat atcatcctta taacaggtac attttcaact taagttttta ctccattatg

2460

cacagtttga gataaataaa tttttgaaat atggacactg aaaaaaaaaa aaaaaaaa

2518

<210>
<211>
<212>
<213>

SEQ ID NO 9
LENGTH, 317
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 9
Met Tyr Asn Met Met Glu Thr Glu Leu Lys Pro Pro Gly Pro Gln Gln
1
5
10
15
Thr Ser Gly Gly Gly Gly Gly Asn Ser Thr Ala Ala Ala Ala Gly Gly
20
25
30
Asn Gln Lys Asn Ser Pro Asp Arg Val Lys Arg Pro Met Asn Ala Phe
35
40
45
Met Val Trp Ser Arg Gly Gln Arg Arg Lys Met Ala Gln Glu Asn Pro
50
55
60
Lys Met His Asn Ser Glu Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys
65
70
75
80
Leu Leu Ser Glu Thr Glu Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg
85
90
95
Leu Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro
100
105
110
Arg Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro
115
120
125
Gly Gly Leu Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly
130
135
140
Val Gly Ala Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr
145
150
155
160
Ala His Met Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp
165
170
175
Gln Leu Gly Tyr Pro Gln His Pro Gly Leu Asn Ala His Gly Ala Ala
180
185
190
Gln Met Gln Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn
195
200
205
Ser Met Thr Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser
210
215
220
Met Ser Tyr Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met
225
230
235
240
Gly Ser Val Val Lys Ser Glu Ala Ser Ser Ser Pro Pro Val Val Thr
245
250
255
Ser Ser Ser His Ser Arg Ala Pro Cys Gln Ala Gly Asp Leu Arg Asp
260
265
270
Met Ile Ser Met Tyr Leu Pro Gly Ala Glu Val Pro Glu Pro Ala Ala
275
280
285
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29

30
-continued

Pro Ser Arg Leu His Met Ser Gln His Tyr Gln Ser Gly Pro Val Pro
290

295

300

Gly Thr Ala Ile Asn Gly Thr Leu Pro Leu Ser His Met
305

310

315

What is claimed is:
1. A method of transforming an adult mesenchymal stem
cell into a pluripotent cell, said method comprising introducing into said adult mesenchymal stem cell an oct4 gene and a
sox 2 gene and culturing said adult mesenchymal stem cell
under conditions to produce expression of said oct4 and sox 2
genes, wherein said expression results in said adult mesenchymal stem cell becoming a pluripotent cell.
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